CannPal Begins Phase 2 Pilot Study for Cannabis-Derived Osteoarthritis Drug for Dogs

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) recently announced the commencement of a Phase 2A pilot dose determination study for the company’s lead drug candidate, CPAT-01, in development for pain and inflammation control in dogs. The clinical trial is an 8 week randomized, double-blind, placebo-controlled study to assess theRead More →